BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiang JF, Lao YC, Yuan BH, Yin J, Liu X, Chen L, Zhong JH. Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget 2017;8:33911-21. [PMID: 28430610 DOI: 10.18632/oncotarget.15411] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Jiang L, Cai X, Li S, Miao Y, Yang X, Lin M, Chen L, He X, Weng Z. Hydroxyethyl Starch Curcumin Enhances Antiproliferative Effect of Curcumin Against HepG2 Cells via Apoptosis and Autophagy Induction. Front Pharmacol 2021;12:755054. [PMID: 34803697 DOI: 10.3389/fphar.2021.755054] [Reference Citation Analysis]
2 Catania R, Chupetlovska K, Borhani AA, Maheshwari E, Furlan A. Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications. Abdom Radiol (NY) 2021;46:5723-34. [PMID: 34519877 DOI: 10.1007/s00261-021-03270-x] [Reference Citation Analysis]
3 Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zhong JH, Li LQ. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol. 2017;5:169-176. [PMID: 28660155 DOI: 10.14218/jcth.2016.00071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Ryon EL, Kronenfeld JP, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, Goel N, Merchant NB, Datta J. Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. J Surg Oncol 2021;123:407-15. [PMID: 33125746 DOI: 10.1002/jso.26282] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Lee HY, Hong SK, Hong SY, Suh S, Han ES, Lee JM, Choi Y, Yi NJ, Lee KW, Suh KS. Outcomes of Living Donor Liver Transplantation in Patients With a History of Ruptured Hepatocellular Carcinoma. Front Surg 2021;8:722098. [PMID: 34733878 DOI: 10.3389/fsurg.2021.722098] [Reference Citation Analysis]
6 Chen S, Wu Z, Shi F, Mai Q, Wang L, Wang F, Zhuang W, Chen X, Chen H, Xu B, Lai J, Guo W. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study. J Cancer Res Clin Oncol 2021. [PMID: 34453221 DOI: 10.1007/s00432-021-03767-4] [Reference Citation Analysis]
7 Que J, Wu HC, Lin CH, Huang CI, Li LC, Ho CH. Comparison of stereotactic body radiation therapy with and without sorafenib as treatment for hepatocellular carcinoma with portal vein tumor thrombosis. Medicine (Baltimore) 2020;99:e19660. [PMID: 32221093 DOI: 10.1097/MD.0000000000019660] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Kim N, You MW. Hepatocellular carcinoma and macrovascular tumor thrombosis: treatment outcomes and prognostic factors for survival. Jpn J Radiol 2019;37:781-92. [PMID: 31522384 DOI: 10.1007/s11604-019-00868-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Su F, Chen KH, Liang ZG, Wu CH, Li L, Qu S, Chen L, Zhu XD, Zhong JH, Li LQ, Xiang BD. Comparison of three-dimensional conformal radiotherapy and hepatic resection in hepatocellular carcinoma with portal vein tumor thrombus. Cancer Med 2018;7:4387-95. [PMID: 30062844 DOI: 10.1002/cam4.1708] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Tong Y, Wang M, Huang H, Zhang J, Huang Y, Chen Y, Pan H. Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line. Exp Ther Med 2019;18:3793-800. [PMID: 31611933 DOI: 10.3892/etm.2019.8027] [Reference Citation Analysis]
11 Sun R, Zhai R, Ma C, Miao W. Combination of aloin and metformin enhances the antitumor effect by inhibiting the growth and invasion and inducing apoptosis and autophagy in hepatocellular carcinoma through PI3K/AKT/mTOR pathway. Cancer Med 2020;9:1141-51. [PMID: 31830378 DOI: 10.1002/cam4.2723] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
12 Dutta D, Tatineni T, Yarlagadda S, Gupte A, Reddy SK, Madhavan R, Nair H, Sasidharan A, Kannan R, Pottayil SG, Holla R, Sudhindran S. Hepatocellular carcinoma patients with portal vein thrombosis treated with robotic radiosurgery: Interim results of a prospective study. Indian J Gastroenterol 2021;40:389-401. [PMID: 34694581 DOI: 10.1007/s12664-021-01172-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Bai Z, Li B, Lin S, Liu B, Li Y, Zhu Q, Wu Y, Yang Y, Tang S, Meng F, Chen Y, Yuan S, Shao L, Qi X. Development and Validation of CAGIB Score for Evaluating the Prognosis of Cirrhosis with Acute Gastrointestinal Bleeding: A Retrospective Multicenter Study. Adv Ther 2019;36:3211-20. [PMID: 31512140 DOI: 10.1007/s12325-019-01083-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
14 Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46:3528-39. [PMID: 33835223 DOI: 10.1007/s00261-021-03069-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Qadan M, Kothary N, Sangro B, Palta M. The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Am Soc Clin Oncol Educ Book 2020;40:1-8. [PMID: 32213090 DOI: 10.1200/EDBK_280811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zhang Y, Zhang Y, Xu H. Effect of Codonopsis pilosula Polysaccharides on the Growth and Motility of Hepatocellular Carcinoma HepG2 Cells by Regulating β -Catenin/TCF4 Pathway. International Journal of Polymer Science 2019;2019:1-7. [DOI: 10.1155/2019/7068437] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Qu J, Lu W, Chen M, Gao W, Zhang C, Guo B, Yang J. Combined effect of recombinant human adenovirus p53 and curcumin in the treatment of liver cancer. Exp Ther Med 2020;20:18. [PMID: 32934683 DOI: 10.3892/etm.2020.9145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Guo X, Wang Y. LncRNA TMPO-AS1 promotes hepatocellular carcinoma cell proliferation, migration and invasion through sponging miR-329-3p to stimulate FOXK1-mediated AKT/mTOR signaling pathway. Cancer Med 2020;9:5235-46. [PMID: 32462698 DOI: 10.1002/cam4.3046] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
19 Zhang X, Xu L, Yang T. miR-31 Modulates Liver Cancer HepG2 Cell Apoptosis and Invasion via ROCK1/F-Actin Pathways. Onco Targets Ther 2020;13:877-88. [PMID: 32099392 DOI: 10.2147/OTT.S227467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Lin J, Jiang H, Yang W, Jiang N, Zheng Q, Huang N, Wang X, Li A, Huang J. Predictive factors of benefit from iodine-125 brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis. Brachytherapy. 2018;pii:S1538-4721(18)30424-0. [PMID: 30467014 DOI: 10.1016/j.brachy.2018.10.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
21 Ban D, Ogura T, Akahoshi K, Tanabe M. Current topics in the surgical treatments for hepatocellular carcinoma. Ann Gastroenterol Surg 2018;2:137-46. [PMID: 29863117 DOI: 10.1002/ags3.12065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
22 Sun J, Zhang Y, Li B, Dong Y, Sun C, Zhang F, Jin L, Chen D, Wang W. PITPNA-AS1 abrogates the inhibition of miR-876-5p on WNT5A to facilitate hepatocellular carcinoma progression. Cell Death Dis 2019;10:844. [PMID: 31700026 DOI: 10.1038/s41419-019-2067-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
23 Sun L, Guo Z, Sun J, Li J, Dong Z, Zhang Y, Chen J, Kan Q, Yu Z. MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway. Biomedicine & Pharmacotherapy 2018;107:168-76. [DOI: 10.1016/j.biopha.2018.07.151] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
24 Chen X, Zhang S, Wang Z, Wang F, Cao X, Wu Q, Zhao C, Ma H, Ye F, Wang H, Fang Z. Supervillin promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma in hypoxia via activation of the RhoA/ROCK-ERK/p38 pathway. J Exp Clin Cancer Res 2018;37:128. [PMID: 29954442 DOI: 10.1186/s13046-018-0787-2] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
25 Bertacco A, Vitale A, Mescoli C, Cillo U. Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection. Per Med 2020;17:83-7. [PMID: 32157952 DOI: 10.2217/pme-2018-0114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Ibrahim C, Parra N, Macedo FI, Yakoub D. Is hepatic resection better than transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis? J Gastrointest Oncol 2019;10:1064-72. [PMID: 31949923 DOI: 10.21037/jgo.2019.09.07] [Reference Citation Analysis]
27 Orcutt ST, Anaya DA. Liver Resection and Surgical Strategies for Management of Primary Liver Cancer. Cancer Control 2018;25:1073274817744621. [PMID: 29327594 DOI: 10.1177/1073274817744621] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 12.3] [Reference Citation Analysis]
28 Pesce A, Boncoraglio A, Basile A, Puleo S. Percutaneous Transhepatic Y-shaped Stent Placement in Portal-superior Mesenteric Vein Tumor Thrombosis Before Right Colectomy. Surg Laparosc Endosc Percutan Tech 2018;28:e30-2. [PMID: 29176370 DOI: 10.1097/SLE.0000000000000496] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
29 Ren QP, Luo YL, Xiao FM, Wen TF, Wu MH, Juan-Wan, Xie ZR. Effect of enhanced recovery after surgery program on patient-reported outcomes and function recovery in patients undergoing liver resection for hepatocellular carcinoma. Medicine (Baltimore) 2020;99:e20062. [PMID: 32443312 DOI: 10.1097/MD.0000000000020062] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Finn RS, Ikeda M, Zhu AX, Sung MW, Baron AD, Kudo M, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Mamontov K, Meyer T, Kubota T, Dutcus CE, Saito K, Siegel AB, Dubrovsky L, Mody K, Llovet JM. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol 2020;38:2960-70. [PMID: 32716739 DOI: 10.1200/JCO.20.00808] [Cited by in Crossref: 100] [Cited by in F6Publishing: 100] [Article Influence: 50.0] [Reference Citation Analysis]
31 Hartl DM, Zafereo ME, Kowalski LP, Randolph GW, Olsen KD, Fernandez-Alvarez V, Nixon IJ, Shaha AR, Angelos P, Shah JP, Ferlito A. Occlusion of the internal jugular vein in differentiated thyroid carcinoma: Causes and diagnosis. Eur J Surg Oncol 2021;47:1552-7. [PMID: 33642089 DOI: 10.1016/j.ejso.2021.02.021] [Reference Citation Analysis]
32 Gao Y, Wang PX, Cheng JW, Sun YF, Hu B, Guo W, Zhou KQ, Yin Y, Li YC, Wang J, Huang JF, Qiu SJ, Zhou J, Fan J, Yang XR. Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. Cancer Med 2019;8:6933-44. [PMID: 31566899 DOI: 10.1002/cam4.2556] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
33 Han Y, Cao G, Sun B, Wang J, Yan D, Xu H, Shi Q, Liu Z, Zhi W, Xu L, Liu B, Zou Y. Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. BMC Gastroenterol 2021;21:393. [PMID: 34670512 DOI: 10.1186/s12876-021-01967-3] [Reference Citation Analysis]
34 Hassnine AA, Elsayed AM. COVID-19 in Cirrhotic Patients: Is Portal Vein Thrombosis a Potential Complication? Can J Gastroenterol Hepatol 2022;2022:5900468. [PMID: 35345818 DOI: 10.1155/2022/5900468] [Reference Citation Analysis]
35 Wang L, Li Q, Zhang J, Lu J. A Novel Prognostic Scoring Model Based on Albumin and γ-Glutamyltransferase for Hepatocellular Carcinoma Prognosis. Cancer Manag Res 2019;11:10685-94. [PMID: 31920379 DOI: 10.2147/CMAR.S232073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
36 Li Z, Xu J, Cui H, Song J, Chen J, Wei J. Bioinformatics analysis of key biomarkers and potential molecular mechanisms in hepatocellular carcinoma induced by hepatitis B virus. Medicine (Baltimore) 2020;99:e20302. [PMID: 32443377 DOI: 10.1097/MD.0000000000020302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Zhang L, Geng Z, Wan Y, Meng F, Meng X, Wang L. Functional analysis of miR-767-5p during the progression of hepatocellular carcinoma and the clinical relevance of its dysregulation. Histochem Cell Biol 2020;154:231-43. [PMID: 32333091 DOI: 10.1007/s00418-020-01878-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Sadik NA, Ahmed NR, Mohamed MF, Ashoush OA. Serum Vascular Endothelial Growth Factor in Patients with Hepatocellular Carcinoma and its Validity as a Tumor Biomarker. TOBIOMJ 2019;9:84-94. [DOI: 10.2174/1875318301909010084] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
39 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
40 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Handa S, Gupta K, Sterpi M, Khan A, Hoskote A, Kasi A. Trends and In-Hospital Outcomes of Splanchnic Vein Thrombosis Associated with Gastrointestinal Malignancies: A Nationwide Analysis. Gastrointest Tumors 2021;8:71-80. [PMID: 33981685 DOI: 10.1159/000513368] [Reference Citation Analysis]